Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Myelofibrosis Resource Center

Featured

News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
Nikolai Podoltsev video thumbnail.
Videos
Current Treatment Options and Recent Developments in Myelofibrosis
03/27/2024

Featuring Nikolai Podoltsev, MD, PhD

Featuring Nikolai Podoltsev, MD, PhD ...
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD,...
03/27/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology
From Oncology
Eytan M Stein, MD
Q&As
Preventing Transformation and Adverse Events Among Patients With Myelofibrosis
03/07/2024

Featuring Eytan M Stein, MD

Featuring Eytan M Stein, MD
Eytan M Stein, MD, shares expert insights on preventing transformation and reducing the symptom burden of adverse events among patients with myelofibrosis.
Eytan M Stein, MD, shares expert insights on preventing transformation and reducing the symptom burden of adverse events among patients with myelofibrosis.
Eytan M Stein, MD, shares expert...
03/07/2024
Oncology
From Oncology
News
Patients With Myelofibrosis Are at Higher Risk for Poor Cardiovascular Outcomes After Heart Failure Hospitalization
03/05/2024

Grace Taylor

Grace Taylor
Orly Leiva, MD, and colleagues examined cardiovascular outcomes for patients with myeloproliferative neoplasms, highlighting increased risks for patients with myelofibrosis.
Orly Leiva, MD, and colleagues examined cardiovascular outcomes for patients with myeloproliferative neoplasms, highlighting increased risks for patients with myelofibrosis.
Orly Leiva, MD, and colleagues...
03/05/2024
Journal of Clinical Pathways
News
Evaluating Clinically Meaningful Symptom Benefits and Symptom Change Threshold Among Patients With Myelofibrosis Treated With Momelotinib
02/27/2024

Jordan Kadish

Jordan Kadish
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Momelotinib displayed clinically...
02/27/2024
Oncology
From Oncology
News
Addition of Parsaclisib to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores Among Patients With Myelofibrosis
02/23/2024

Jordan Kadish

Jordan Kadish
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
The addition of parsaclisib to...
02/23/2024
Oncology
From Oncology
Aaron Gerds, MD
Videos
Mitigating Potential Treatment Risks Among Patients With Myelofibrosis
02/02/2024

Featuring Aaron Gerds, MD

Featuring Aaron Gerds, MD
Aaron Gerds, MD, examines potential treatment risks for patients with myelofibrosis and how to mitigate them in order to achieve the best possible outcomes.
Aaron Gerds, MD, examines potential treatment risks for patients with myelofibrosis and how to mitigate them in order to achieve the best possible outcomes.
Aaron Gerds, MD, examines...
02/02/2024
Oncology
From Oncology

Newsfeed

News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways
News
Rusfertide Treatment Strengthens Response and Decreases Erythrocytosis Among Patients With Polycythemia Vera
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology
News
Patients With Myelofibrosis Are at Higher Risk for Poor Cardiovascular Outcomes After Heart Failure Hospitalization
03/05/2024

Grace Taylor

Grace Taylor
Orly Leiva, MD, and colleagues examined cardiovascular outcomes for patients with myeloproliferative neoplasms, highlighting increased risks for patients with myelofibrosis.
Orly Leiva, MD, and colleagues examined cardiovascular outcomes for patients with myeloproliferative neoplasms, highlighting increased risks for patients with myelofibrosis.
Orly Leiva, MD, and colleagues...
03/05/2024
Journal of Clinical Pathways
News
Evaluating Clinically Meaningful Symptom Benefits and Symptom Change Threshold Among Patients With Myelofibrosis Treated With Momelotinib
02/27/2024

Jordan Kadish

Jordan Kadish
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that analyzed the appropriateness of the symptom change threshold used in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Momelotinib displayed clinically...
02/27/2024
Oncology
News
Addition of Parsaclisib to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores Among Patients With Myelofibrosis
02/23/2024

Jordan Kadish

Jordan Kadish
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
The addition of parsaclisib to ruxolitinib treatment decreased spleen volume, improved symptom scores, and demonstrated acceptable safety among patients with primary or secondary myelofibrosis, according to a phase 2 study.
The addition of parsaclisib to...
02/23/2024
Oncology
News
Ruxolitinib Strengthens Survival Outcomes Among High-Risk Patients With Myelofibrosis
01/22/2024

Jordan Kadish

Jordan Kadish
Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.
Ruxolitinib treatment strengthened survival outcomes among high-risk patients with myelofibrosis, according to findings from a population-based retrospective study.
Ruxolitinib treatment...
01/22/2024
Oncology
Conference Coverage
The Potential of Pelabresib Plus Ruxolitinib For Treating Patients With Myelofibrosis: The MANIFEST-2 Study
12/08/2023

Edited by: Grace Taylor

Edited by: Grace Taylor
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD,...
12/08/2023
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways

Conference Coverage

Nikolai Podoltsev video thumbnail.
Videos
Current Treatment Options and Recent Developments in Myelofibrosis
03/27/2024

Featuring Nikolai Podoltsev, MD, PhD

Featuring Nikolai Podoltsev, MD, PhD ...
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD,...
03/27/2024
Journal of Clinical Pathways
Douglas Tremblay, MD
Conference Coverage
Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis
01/03/2024

Featuring Douglas Tremblay, MD

Featuring Douglas Tremblay, MD ...
At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the 2023 ASH Annual Meeting,...
01/03/2024
Oncology
Conference Coverage
The Potential of Pelabresib Plus Ruxolitinib For Treating Patients With Myelofibrosis: The MANIFEST-2 Study
12/08/2023

Edited by: Grace Taylor

Edited by: Grace Taylor
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
A study by Raajit K. Rampal, MD,...
12/08/2023
Journal of Clinical Pathways
Conference Coverage
Key Factors Influencing Survival Rates in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
12/07/2023

Edited by Grace Taylor

Edited by Grace Taylor
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A study by Helen Ajufo, MD, MS,...
12/07/2023
Journal of Clinical Pathways
Ruben A. Mesa, MD, FACP, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Videos
Novel Advances in the Treatment of Patients With Myelofibrosis
11/07/2023

Featuring Ruben A. Mesa, MD, FACP

Featuring Ruben A. Mesa, MD, FACP ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.
At the 2023 Lymphoma, Leukemia &...
11/07/2023
Lymphoma, Leukemia & Myeloma Network
News
Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis
03/02/2023

Marta Rybczynski

Marta Rybczynski
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing...
03/02/2023
Journal of Clinical Pathways
Conference Coverage
Exploring Use of Navitoclax in Conjunction With Ruxolitinib in Patients With MF Who are JAKi-Naïve
01/31/2023

Yvette C Terrie

Yvette C Terrie
Findings from a recent study indicated that the combination of navitoclax and ruxolitinib for the treatment of primary or secondary MF among patients who were classified as JAKi-naïve provided promising and suggestive evidence of disease...
Findings from a recent study indicated that the combination of navitoclax and ruxolitinib for the treatment of primary or secondary MF among patients who were classified as JAKi-naïve provided promising and suggestive evidence of disease...
Findings from a recent study...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Machine Learning Model Beneficial in Predicting Overall Survival in Patients With Myelofibrosis
01/31/2023

Yvette C Terrie

Yvette C Terrie
Findings from a recent study indicated that the use of a simple machine learning model known as the AIPSS-MF model was associated with an elevated rate of accuracy with regard to predicting OS in patients with primary and secondary MF,...
Findings from a recent study indicated that the use of a simple machine learning model known as the AIPSS-MF model was associated with an elevated rate of accuracy with regard to predicting OS in patients with primary and secondary MF,...
Findings from a recent study...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
01/31/2023

Yvette C Terrie

Yvette C Terrie
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology
Tony Mok, MD
Conference Coverage
Adagrasib Improved Survival and Response Among Patients With KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
06/17/2024
Tony Mok, MD
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
According to results from the...
06/17/2024
Oncology
William J. Gradishar, MD
Videos
HR-Positive and HER2-Negative Breast Cancer Treatment Updates
06/04/2024
William J. Gradishar, MD
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD, details the latest advancements in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer.
William J. Gradishar, MD,...
06/04/2024
Journal of Clinical Pathways
Natasha Leighl, MD
Conference Coverage
Subcutaneous vs Intravenous Amivantamab Plus Lazertinib for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
06/01/2024
Natasha Leighl, MD
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.
Natasha Leighl, MD, discussed...
06/01/2024
Oncology
Lalan Wilfong, MD
Videos
Balancing the Benefits and Risks of Value-Based Care Arrangements
05/16/2024
Lalan Wilfong, MD
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his key takeaways from the Community Oncology Conference session on defining value-based care in oncology.
Lalan Wilfong, MD, discusses his...
05/16/2024
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Recent Stories

News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
MorphoSys’ Myelofibrosis Drug Results Cast Doubt on Novartis Acquisition Deal
05/08/2024
Grace Taylor, MS, MA
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion acquisition deal with Novartis may be in jeopardy due to reports regarding safety problems with its investigational myelofibrosis drug pelabresib.
MorphoSys’ $2.9 billion...
05/08/2024
Journal of Clinical Pathways
News
Dietary Recommendations for Patients With Myelofibrosis
04/22/2024

Grace Taylor

Grace Taylor
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help patients with myelofibrosis have more energy, better immune function, and more.
A balanced diet can help...
04/22/2024
Journal of Clinical Pathways
Nikolai Podoltsev video thumbnail.
Videos
Current Treatment Options and Recent Developments in Myelofibrosis
03/27/2024

Featuring Nikolai Podoltsev, MD, PhD

Featuring Nikolai Podoltsev, MD, PhD ...
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD,...
03/27/2024
Journal of Clinical Pathways
News
Disease Progression for Patients With Low-Risk Myelofibrosis Participating in the MOST Study
03/26/2024

Grace Taylor

Grace Taylor
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined disease progression for patients with low-risk myelofibrosis participating in the prospective observational MOST study.
A group of researchers examined...
03/26/2024
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement